StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Allogene Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Allogene Therapeutics's profit margin for the twelve months ending Dec 31, 2024 was -1170863.6%. For fiscal 2024 it was -1170863.6%, against -344489.5% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 2024-1170863.6%−826374.2
FY2023Dec 31, 2023-344489.5%−126275.4
FY2022Dec 31, 2022-218214.1%−218054.5
FY2021Dec 31, 2021-159.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-919.8%+359225.7
Q1 FY2024Mar 31, 2024-295454.5%+37772.1
Q4 FY2023Dec 31, 2023-408466.7%−34332.1
Q3 FY2023Sep 30, 2023-283122.7%+28884.7
Q2 FY2023Jun 30, 2023-360145.5%−234692.3
Q1 FY2023Mar 31, 2023-333226.7%−131670.3
Q4 FY2022Dec 31, 2022-374134.6%−374134.7
Q3 FY2022Sep 30, 2022-312007.4%−152444.1
Q2 FY2022Jun 30, 2022-125453.1%+35765.1
Q1 FY2022Mar 31, 2022-201556.4%−201470.3
Q4 FY2021Dec 31, 20210.1%–
Q3 FY2021Sep 30, 2021-159563.3%–
Q2 FY2021Jun 30, 2021-161218.2%–
Q1 FY2021Mar 31, 2021-86.1%–

More Allogene Therapeutics figures

See a number that looks wrong?